NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
April 29, 2024
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
March 16, 2023
Related Post
-
-
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
April 26, 2024
-
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
April 26, 2024
-
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024